Targeting c-MET/HGF Signaling Pathway in Upper Gastrointestinal Cancers: Rationale and Progress

Gholamin, Sharareh; Fiuji, Hamid; Maftouh, Mina; Mirhafez, Reza; Shandiz, Fatemeh Homaei; Avan, Amir
December 2014
Current Drug Targets;Dec2014, Vol. 15 Issue 14, p1302
Academic Journal
Aberrant activation of receptor-tyrosine kinase c-Met/HGF pathway is shown to be associated with cell proliferation, invasion, metastasis and poor-prognosis in several tumor types, including upper gastrointestinal-malignancies. The interaction of c-Met with multiple signalling-pathways involved in tumorigenic-properties and invasive-phenotype has gained substantial attention, suggesting its role as an intriguing-target for cancer-therapy. In recent years, there have been considerable efforts in the development of effective c-Met inhibitors with potential clinical-applications and one of them, crizotinib (dual c-Met/ALK inhibitor), has recently been approved for lung-cancers with ALKrearrangement. However several important questions remain to be answered on the molecular mechanisms underlying the antitumor effects of crizotinib, as well as on its possible role in the treatment of different tumor types, including uppergastrointestinal- cancers. The aim of this review is to give an overview on critical role of the c-Met/HGF pathway in cancer, and the preclinical/clinical studies on c-Met inhibitors. There are accumulating evidences on therapeutic potential of c-Met inhibitors for the treatment of other malignancies, such as gastric and pancreatic cancers. However, further investigations are needed to identify determinants of the activity of c-Met inhibitors, through the analysis of genetic/ environmental alterations affecting c-Met and parallel pro-cancer pathways; mechanisms result in developing resistance to anti-c-Met agents; and selection of patients that might benefit from therapy. These studies will be essential to improve the selectivity/efficacy of future anticancer strategies of c-Met targeted-therapies in the treatment of upper gastrointestinal- cancers.


Related Articles

  • In Search of Novel Molecular Targets in Cancer: The Diacyglycerol Pathways. Lorenzo, Patricia S. // Hawaii Medical Journal;Oct2004, Vol. 63 Issue 10, p318 

    Focuses on molecular pathways that are important in the development and progression of cancer. Biology of protein kinase C (PKC) and its role in disease; Rationale of PKC as a molecular target in cancer therapy; Chemotherapeutic drugs that target PKC.

  • Targeting platelet-derived growth factor (PDGF) signaling in gastrointestinal cancers: preclinical and clinical considerations. Abdel-Rahman, Omar // Tumor Biology;Jan2015, Vol. 36 Issue 1, p21 

    The prognosis of advanced gastrointestinal malignancies has been generally dreadful prompting robust search for better, more personalized, and more tailored treatments. In recent years, important signaling pathways leading to tumor progression and metastasis have been discovered with the...

  • TGF-β Signaling in Gastrointestinal Cancer Stem Cells. Chohee Yun; Mendelson, Jonathan; Woo Kim, Young; Mishra, Lopa // Current Cancer Therapy Reviews;2008, Vol. 4 Issue 3, p196 

    The TGF-Î’ signaling pathway plays a significant role in various biological phenomena such as cell growth, embryogenesis, differentiation, morphogenesis and apoptosis. Gastrointestinal endodermal stem cells, influenced by TGF-Î’ signals, undergo asymmetric cell division that leads to...

  • The emerging role of Slit-Robo pathway in gastric and other gastro intestinal cancers. Tingting Huang; Wei Kang; Cheng, Alfred S. L.; Jun Yu; Ka Fai To; Huang, Tingting; Kang, Wei; Yu, Jun; To, Ka Fai // BMC Cancer;12/16/2015, Vol. 15, p1 

    Gastric cancer remains one of the most common cancers worldwide and one of the leading cause for cancer-related deaths. Due to the high frequency of metastasis, it is still one of the most lethal malignancies in which kinds of signaling pathways are involved in. The Roundabout (ROBO) receptors...

  • Targeting Notch signaling in pancreatic cancer patients -- rationale for new therapy. Mysliwiec, P.; Boucher, M. J. // Advances in Medical Sciences (De Gruyter Open);2009, Vol. 54 Issue 2, p136 

    Pancreatic cancer is one of the most aggressive and devastating human malignancies. Despite new knowledge in the molecular profile of pancreatic cancer and its precursor lesions, survival rates have changed very little over the last 40 years. Therefore, a better understanding of the detailed...

  • AR-Signaling in Human Malignancies: Prostate Cancer and Beyond. Schweizer, Michael T.; Yu, Evan Y. // Cancers;Jan2017, Vol. 9 Issue 1, p7 

    In the 1940s Charles Huggins reported remarkable palliative benefits following surgical castration in men with advanced prostate cancer, and since then the androgen receptor (AR) has remained the main therapeutic target in this disease. Over the past couple of decades, our understanding of...

  • C-KIT Signaling in Cancer Treatment. Stankov, Karmen; Popovic, Stevan; Mikov, Momir // Current Pharmaceutical Design;May2014, Vol. 20 Issue 17, p2849 

    Tumor progression is strongly associated with the activity of receptor tyrosine kinases (RTKs) and their intracellular signal transduction pathways, which regulate several cell functions including proliferation, apoptosis, motility, adhesion and angiogenesis. Detailed structural and functional...

  • Targeting MET in cancer: rationale and progress. Gherardi, Ermanno; Birchmeier, Walter; Birchmeier, Carmen; Woude, George Vande // Nature Reviews Cancer;Sep2012, Vol. 12 Issue 9, p637 

    A correction to the article "Targeting MET in cancer: rationale and progress" that was published in 2012 issue is presented.

  • ANGIOGENEZA TUMORALÄ‚ - IMPLICAÅ¢II ÃŽN TERAPIA CANCERELOR. Miron, L.; Gafton, B.; Marinca, M. // Jurnalul de Chirurgie;2010, Vol. 6 Issue 2, p104 

    Neovascularization is a crucial component of cancer cell growth and progression. Cancer cells are dependent on blood vessels for growth and metastases. Angiogenesis is finely balanced by pro- and anti-angiogenetic factors. Under normal conditions, the balance leans toward the anti-angiogenetic...

  • Combination of Anti-EGFR Drugs with Anti-Angiogenic or Other Signal Transduction Inhibitors as a Rational Approach to Cancer Therapy. Morelli, Maria Pia; Spratlin, Jennifer; Eckhardt, S. Gail // Current Cancer Therapy Reviews;2007, Vol. 3 Issue 4, p284 

    Activation of the epidermal growth factor receptor (EGFR)-dependent intracellular signaling pathway has a relevant role in the development and the progression of several human cancers. However, EGFR-targeted therapies have a significant clinical activity only in a subgroup of cancer patients...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics